 |
| ||||||||||||||
 |
||||||||||||||
|
|
 |
| We perform non-clinical experiments to discover and develop novel central nervous system therapeutic treatments for neuropsychiatric diseases including schizophrenia and depression. |
| * OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989 |